Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 451

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1

Flint, Julia, Panchal, Sonia, Hurrell, Alice, van de Venne, Maud, Gayed, Mary, Schreiber, Karen, Arthanari, Subha, Cunningham, Joel, Flanders, Lucy, Moore, Louise, Crossley, Amy, Purushotham, Neetha, Desai, Amisha, Piper, Madeleine, Nisar, Mohamed, Khamashta, Munther, Williams, David, Gordon, Caroline, Giles, Ian, on behalf of the BSR and BHPR Standards, Guidelines and Audit Working Group · 2016 · Rheumatology

Abstract

The prescribing of many drugs in pregnancy is complicated by a lack of knowledge regarding their compatibility leading to patient misinformation and withdrawal/denial of disease-ameliorating therapies. This situation should be avoided because active rheumatic disease is associated with adverse pregnancy outcomes [ 1 ] and there is growing evidence of drug safety in pregnancy. To provide evidence-based recommendations, which do not imply a legal obligation, for clinicians when prescribing anti-rheumatic drugs before/during pregnancy and breastfeeding that update previous recommendations [ 2 , 3 ]. For recommendations on prescribing other drugs in pregnancy and breastfeeding see the British Society of Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines part II [ 4 ]. Health professionals directly involved in managing patients with rheumatic disease in the UK who are (or planning to become) pregnant and/or breastfeeding, men planning to conceive and patients who have accidentally conceived while taking these medications. This guideline does not cover the management of infertility or the indications for these drugs in specific rheumatic diseases in pregnancy. Specific questions were considered in relation to each drug. Should it be stopped pre-conception? Is it compatible with pregnancy? Is it compatible with breastfeeding? Where possible, recommendations are made regarding compatibility with paternal exposure. These findings are summarized in Table 1 . A description of evidence and full recommendations are given in the full guideline provided as supplementary data , available at Rheumatology Online. Summary of drug compatibility in pregnancy and breastfeeding For further information and caveats, see relevant recommendations and main text in executive summary and full guideline. a Data are limited. b In healthy full-term infants only. c Conception may be enhanced by stopping SSZ for 3 months prior to conception. d Suggested monitoring of maternal blood pressure, renal function, blood glucose and drug levels. e Only consider in severe or life-/organ-threatening maternal disease. f Unintentional first trimester exposure is unlikely to be harmful. g Unlikely to be harmful. Prednisolone is compatible with each trimester of pregnancy [level of evidence (LOE) 1 ++, grade of recommendation (GOR) A, strength of agreement (SOA) 100%]. Prednisolone is compatible with breastfeeding (LOE 2−, GOR D, SOA 98.9%). Prednisolone is compatible with paternal exposure (LOE 2+, GOR D, SOA 98.9%). Methylprednisolone has rates of placental transfer similar to prednisolone with equivalent anti-inflammatory effects at 80% of prednisolone dose and would therefore be expected to be compatible with pregnancy, breastfeeding and paternal exposure (LOE 4, GOR D, SOA 93.7%). HCQ remains the antimalarial of choice in women planning a pregnancy with rheumatic disease in need of treatment and should be continued during pregnancy (LOE 1 ++, GOR A, SOA 100%). HCQ is compatible with breastfeeding (LOE 4, GOR D, SOA 98.9%). Men should not be discouraged from taking HCQ while trying to conceive (LOE 2−, GOR D, SOA 98.9%). MTX at any dose should be avoided in pregnancy and stopped 3 months in advance of conception (LOE 2−, GOR D, SOA 100%). In women treated with low-dose MTX within 3 months prior to conception, folate supplementation (5 mg/day) should be continued prior to and throughout pregnancy (LOE 1, GOR B, SOA 98.4%). In the case of accidental pregnancy on low-dose MTX, the drug should be stopped immediately, folate supplementation (5 mg/day) continued and a careful evaluation of foetal risk carried out by local experts (LOE 4, GOR D, SOA 100%). MTX cannot be recommended in breastfeeding because of theoretical risks and insufficient outcome data (LOE 4, GOR D, SOA 100%). Based on limited evidence, low-dose MTX may be compatible with paternal exposure (LOE 2+, GOR D, SOA 95.8%). SSZ with folate supplementation (5 mg/day) is compatible throughout pregnancy (LOE 2+, GOR C, SOA 100%). SSZ is compatible with breastfeeding in healthy, full-term infants (LOE 4, GOR D, SOA 100%). Men taking SSZ may have reduced fertility. There is no evidence, however, that conception is enhanced by stopping SSZ for 3 months prior to conception unless conception is delayed >12 months when other causes of infertility should also be considered (LOE 3, GOR D, SOA 97.4%). Based on limited evidence, LEF may not be a human teratogen but it is still not recommended in women planning pregnancy (LOE 2+, GOR C, SOA 100%). Women on LEF considering pregnancy should stop and undergo cholestyramine washout before switching to alternative medication compatible with pregnancy (LOE 2+, GOR C, SOA 100%). There is no human evidence of increased congenital abnormalities on LEF if washout is given. Therefore, if accidental conception occurs on LEF, the drug should be stopped immediately and cholestyramine washout given until plasma levels are undetectable (L

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kev404

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 451

Metadata

Authors
Flint, J., Panchal, S., Hurrell, A., van de Venne, M., Gayed, M., Schreiber, K., Arthanari, S., Cunningham, J., Flanders, L., Moore, L., Crossley, A., Purushotham, N., Desai, A., Piper, M., Nisar, M., Khamashta, M., Williams, D., Gordon, C., Giles, I., & on behalf of the BSR and BHPR Standards, G. A. A. W. G.
Venue
Rheumatology
Published
2016-01-10
Volume
55
Issue
9
Pages
1693-1697
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
OpenAlex
W2275120634
Cited by
451
References
4
FWCI
52.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1. https://app.cochat.ai/papers/10.1093/rheumatology/kev404
The paper
Flint, J., Panchal, S., Hurrell, A., van de Venne, M., Gayed, M., Schreiber, K., Arthanari, S., Cunningham, J., Flanders, L., Moore, L., Crossley, A., Purushotham, N., Desai, A., Piper, M., Nisar, M., Khamashta, M., Williams, D., Gordon, C., Giles, I., & on behalf of the BSR and BHPR Standards, G. A. A. W. G. (2016). BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1. Rheumatology. https://doi.org/10.1093/rheumatology/kev404

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.